repaglinide tablets

1. Repaglinide is a short-acting insulin secretagogue; Repaglinide lowers blood sugar levels by promoting the release of insulin from the pancreas. This effect depends on the functional beta cells in the pancreatic islets. 2. Repaglinide binds to receptors on beta cells to close ATP-dependent potassium channels in the beta cell membrane, depolarizes beta cells, opens calcium channels, and increases the influx of calcium. This process induces beta cells to secrete insulin. 3. When patients with type 2 diabetes take repaglinide orally, they experience an insulin secretion response within 30 minutes after a meal. This can cause a decrease in blood sugar during meals. Plasma repaglinide levels drop rapidly, and 4 hours after taking the drug, the drug concentration in the plasma of patients with type 2 diabetes is very low. Studies have shown that taking 0.5-4 mg of repaglinide in type 2 diabetes reduces blood sugar concentration in a dose-dependent manner. 4. Clinical research results show that repaglinide should be taken before meals. This product should usually be taken within 15 minutes before a meal, and the medication time can also be controlled 0-30 minutes before a meal.

The main ingredient of this product is repaglinide. Chemical name: S(+)-2-ethoxy-4[2-[[3-methyl-1-[2-(1-piperidinyl)phenyl]-butyl]amino-2-oxyethyl]benzoic acid.

This product is white or off-white tablets.

It is used for patients with type 2 diabetes (non-insulin-dependent) whose high blood sugar cannot be effectively controlled by diet control, weight loss and exercise. Repaglinide tablets can be used in combination with metformin. When the two are used together, they can achieve a synergistic effect in controlling blood sugar than when they are used alone.

1. Repaglinide tablets should be taken before the main meal (i.e. before meals). An insulin secretion-promoting response will occur within 30 minutes of oral administration of this product. This drug is usually taken within 15 minutes before meals, and the time of taking the drug can also be controlled within 0-30 minutes before meals. 2. Please take repaglinide tablets as prescribed by your doctor. The dosage varies from person to person and depends on personal blood sugar. The recommended starting dose is 0.5 mg, which can be adjusted weekly or every two weeks if necessary. The recommended starting dose for patients receiving other oral hypoglycemic drugs who switch to repaglinide tablets is 1 mg. 3. The maximum recommended single dose is 4 mg, taken with meals. However, the maximum daily dose should not exceed 16 mg. 4. When patients with type 2 diabetes who can usually control blood sugar well with diet experience temporary control failure, short-term use of repaglinide can effectively control

Like other oral hypoglycemic drugs, taking repaglinide may cause blood sugar changes, such as hyperglycemia and hypoglycemia. Like every diabetes treatment, the occurrence of these reactions depends on individual factors, such as eating habits, dosage, exercise and stress. The clinical application of repaglinide and other hypoglycemic drugs shows that the following adverse reactions may occur when taking repaglinide: According to the incidence of adverse reactions, they are defined as follows: Rare adverse reactions: incidence 1/10000, 1/1000. Very rare adverse reactions: incidence 1/10000. 1. Immune system disorders Allergic reactions Skin allergic reactions such as itching, redness, and urticaria may occur. Very rarely, extensive allergic reactions or immune reactions such as vasculitis occur. 2. Metabolic and nutritional disorders Hyperglycemia Symptoms of hyperglycemia usually appear gradually and may include nausea, drowsiness, increased urine output, thirst and loss of appetite. Rare adverse reactions: Hypoglycemia Like other hypoglycemic drugs, taking repaglinide may cause hypoglycemia. Symptoms include anxiety, dizziness, sweating, tremor, hunger and inattention. These reactions are usually mild and can be easily corrected by giving carbohydrates. If they are more severe, glucose can be infused with the help of others. Combination with other drugs may increase the risk of hypoglycemia. 3. Eye abnormalities Very rare: Visual abnormalities Changes in blood sugar levels are known to cause temporary visual abnormalities, especially when starting treatment with hypoglycemic drugs. These changes are usually transient. 4. Gastrointestinal discomfort Rare: Abdominal pain, nausea Very rare: Diarrhea, vomiting and constipation Gastrointestinal reactions such as abdominal pain, diarrhea, nausea, vomiting and constipation have been reported in clinical trials. Compared with other oral insulin secretion-promoting drugs, the frequency and severity of these symptoms are no different. Based on post-marketing experience, individual cases of hypoglycemia have been received when repaglinide is used in combination with metformin or thiazolidinediones. 5. Skin and subcutaneous tissue abnormalities Rare: Allergic reactions Skin allergic reactions such as itching, rash, and urticaria may occur. Due to the different chemical structures, there is no reason to suspect that cross-allergic reactions with sulfonylurea drugs may occur. Very rarely, extensive allergic reactions or immune reactions such as vasculitis occur. 6. Hepatobiliary disorders Liver dysfunction is very rare. Reports of severe liver dysfunction: However, the relationship with repaglinide has not been established. 7. Studies Very rare: Elevated liver enzymes Individual cases reported elevated liver enzymes during treatment with repaglinide. Most cases were mild and transient, and very few patients stopped treatment due to elevated liver enzymes.

1. Patients with known hypersensitivity to repaglinide or any excipients in this product. 2. Patients with type 1 diabetes (insulin-dependent, IDDM). 3. Patients with diabetic ketoacidosis with or without coma. 4. Pregnant or lactating women. 5. Children under 8 years old. 6. Patients with severe renal or hepatic insufficiency. 7. When combined with CYP3A4 inhibitors or inducers.

Precautions for children: Repaglinide has not been studied in patients under 18 years of age. Precautions for pregnancy and lactation: It has not been studied in pregnant or lactating women. Therefore, the safety of repaglinide for pregnant women cannot be evaluated. Repaglinide has not been found to be teratogenic in animal studies. In a high-dose exposure study on rats in late pregnancy and lactation, non-teratogenic abnormal limb growth of fetuses and pups was observed. Repaglinide was found in the milk of experimental animals. It is recommended that pregnant and lactating women not use it. Precautions for the elderly: Repaglinide tablets have not been studied in patients over 75 years old. Therefore, patients over 75 years old should not use it.

1. Some drugs are known to affect glucose metabolism. Therefore, doctors should consider possible drug interactions. 2. In vitro studies have shown that the metabolism of repaglinide is affected by CYP2C8 and CYP3A4. 3. Clinical study data conducted in healthy volunteers showed that CYP2C8 is the enzyme that plays a major role in the metabolism of repaglinide, while the effect of strong CYP3A4 inhibitors is limited. However, if the effect of CYP2C8 is inhibited, the effect of CYP3A4 will be relatively enhanced. Therefore, the metabolism and clearance of repaglinide may be changed due to the inhibition or induction of cytochrome P450. Therefore, extreme caution should be exercised when using CYP2C8 and CYP3A4 inhibitors simultaneously with repaglinide. 4. A drug-related study conducted in healthy volunteers.

Protect from light and store in a sealed container at room temperature.

1.0mg

60 months.

Beijing Foyou Pharma Co., Ltd.

• Founded in:

  1999-02-03

• Address:

  No. 8 Guangyuan East Street, Tongzhou Industrial Development Zone, Tongzhou District, Beijing

• Tax NO.:

  91110112700216160K

• Registered Funds:

  480 million yuan

• Website:

  Log in to view

• Email:

  Log in to view